Investigating DYNE-101 and DYNE-251, two therapies being developed by Dyne Therapeutics for the treatment of myotonic dystrophy and DMD.

Executed on:Mar 6, 2024 5:00 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: University of WashingtonAssociate Professor of Neurology at University of Washington and a researcher at the Seattle Wellstone Center.
Manages ~15 patients with myotonic dystrophy type 1 (DM1).
Researches focuses on inclusion body myositis, facioscapulohumeral muscular dystrophy, and ALS (funded throug the NIH), and clinical interests focus on neuromuscular disorders, such as motor neuron disease (ALS), myasthenia gravis, peripheral neuropathies and muscular dystrophies including FSHD.

Interview Goal

This call will discuss the current standard of care for myotonic dystrophy and duchenne muscular dystrophy. There will also be an analysis of the phase 1/2 ACHIEVE and DELIVER clinical trials on DYNE-101 and DYNE-251.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.